Aspergillosis

FDA Approves Treatment for Invasive Fungal Infection

Published in Medical Letter on the CDC and FDA, February 18th, 2001

The U.S. Food and Drug Administration (FDA) has approved Cancidas (caspofungin acetate) Intravenous Infusion, an anti-fungal medication for patients who are unresponsive to or cannot tolerate standard therapies for the invasive form of aspergillosis.

Cancidas is the first approved drug in a class of anti-fungal agents called echinocandins, which are believed to work by disrupting the creation of fungal cell walls.

Invasive aspergillosis is a term used to describe a group of fungal infections caused by the fungus Aspergillus. Most healthy individuals are unaffected by this common fungus; however exposed individuals with weakened or abnormal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2001-02-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry